Contrast-Enhanced Digital Mammography as Supplemental Exam
Supplemental imaging with CEDM may help detect cancer among women at high risk for cancer.
Contrast-enhanced digital mammography (CEDM) could be valuable as a supplemental imaging exam for women at increased risk for breast cancer who do not meet the criteria for MRI or for whom access to MRI is limited, according to a study published in the European Journal of Radiology.
Researchers from Memorial Sloan Kettering Cancer Center in New York, NY, undertook a pilot study to prospectively compare screening CEDM to breast MRI in women with an increased risk for breast cancer
A total of 318 women participated in the study; 307 were evaluable. All underwent CEDM within 30 days of a scheduled screening MRI; CEDM was interpreted blinded to MRI. The reference standard was defined as a combination of pathology and 2-year imaging follow-up.
The results revealed two invasive cancers and one ductal carcinoma in situ at the first round of screening: MRI detected all three cancers and CEDM detected the two invasive cancers. None of the three cancers was seen on the low energy mammograms, comparable to conventional mammography.
The researchers found five additional screen-detected cancers at 2-year imaging follow-up, but no palpable cancers. The positive predictive value 3 (PPV3) for CEDM was 15% and 14% for MRI. The specificity of CEDM and MRI were 94.7% and 94.1% respectively.
The researchers concluded that CEDM could be valuable as a supplemental imaging exam for women at increased risk for breast cancer who do not meet the criteria for MRI or for whom access to MRI is limited. Further study is required, however.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
